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Therapeutic strategies for non-small cell lung carcinoma
(NSCLC) include surgery, chemotherapy and radiation. Many
NSCLC patients present with advanced disease that is not treatable
by surgery or does not respond to chemotherapy or radiation treat-
ment. An alternative therapeutic approach is the use of allogeneic
hematopoietic stem cell transplantation (HSCT) that utilizes the
responsiveness of a donor T lymphocyte graft to respond against
histocompatibility antigens present on lung cancer cells. It has
been shown that a beneficial graft-versus-tumor (GVT) response
is associated with a major complication of HSCT, graft-versus-
host disease (GVHD). Allogeneic HSCT has been utilized to treat
a number of hematologic malignancies and recently selected epi-
thelial solid tumors. The use of this procedure resulted in regres-
sion of renal cell carcinoma lung metastases and a case report
demonstrated the elimination of NSCLC following HSCT. Given
these findings, we utilized major histocompatibility antigen mis-
matched murine bone marrow transplantation (BMT) models and
bioluminescence imaging to test the hypothesis that the allogeneic
immune response that develops following allogeneic HSCT will be
effective in controlling growth of lung cancer. Our results demon-
strated that while GVHD did not develop following reduced inten-
sity (RIC) conditioning and allogeneic donor lymphocyte infusion
(DLI) 28 days after BMT, DLI failed to limit the growth of lung
tumors. In contrast, when DLI was given after lethal myeloablative
conditioning and BMT, a significant reduction in lung tumor
growth was observed in the absence of GVHD. In line with a reduc-
tion in tumor growth, trafficking studies demonstrated that alloge-
neic donor cells migrated at an increased frequency to the lungs of
myeloablated recipients compared to those conditioned with the
RIC regimen. These studies demonstrate the potential efficacy of
allogeneic immunotherapy and provide a model system to study al-
ternative therapeutic options in the treatment of malignancies of
the lung.Gas Exchange Outcomes in Criticall Ill Stem Cell Transplant
Recipients who Received Nebulized Dornase Alfa
Mean
PF ratio
95% CI
(p-value vs
baseline)
Mean
FiO2
95% CI
(p-value vs
baseline)
Baseline 235.8 147.5 - 324.0 0.54 0.33 - 0.76
24 hour 252.8 166.5 - 339.1
(p5 0.6461)
0.53 0.36 - 0.71
(p5 0.9060)
48 hour 251.9 165.9 - 338.9
(p5 0.6725)
0.45 0.34 - 0.56
(p5 0.2610)435
GVHD FOLLOWED BY FULL MYELOID AND LYMPHOID DONOR CHIME-
RISM AFTER CADAVERIC LIVER TRANSPLANTATION
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Introduction:Using hematopoietic donor engraftment as a way to
establish immune tolerance in solid organ transplantation remains
an attractive but elusive goal. We report a case of orthotopic liver
transplantation (OLT)-related aGVHD followed by full chime-
rism of highly HLA-mismatched myeloid and lymphoid donor
cells.
Case report: A 58-year old male with HCV cirrhosis underwent
OLT from a sex and blood type matched (O+) deceased donor.
HLA typing of the donor and recipient demonstrated only one
shared antigen on DRB1. On post-op day (POD) 42, profound pan-
cytopenia developed. BM Bx showed aplastic anemia. On POD 62,
the patient developed grade III skin aGVHD. Methylprednisolone
(1 mg/kg) was added to tacrolimus. Infliximab (10 mg/kg) was given
on POD 81 and 88. The rash and blood counts gradually improved.
Immunosuppression and hematopoietic growth factors were tapered
and blood and transfusion requirements decreased substantially.
Molecular-based HLA typing of PB nucleated cells on POD 71
showed a major population of donor cells. VNTR/STR chimerism
analysis at the D1S80 locus showed 100% donor type in BM
(POD 98) and PB CD3+ and CD33+ compartments (POD 103).Skin GVHD resolved and counts remained stable with modest
growth factor support and periodic transfusion of red cells and plate-
lets.
Discussion:GHVD occurs in approximately 1% of OLT’s and is
a life-threatening complication. It is mediated by passenger lym-
phocytes across major HLA barriers and facilitated by permissive
antigen sharing between donor and recipient. While donor chime-
rism of lymphoid cells is often seen in these cases, full hematopoi-
etic engraftment has only been documented once. Our patient and
donor shared a single class II HLA antigen. After complete sup-
pression of host hematopoiesis, sustained donor lymphoid and my-
eloid engraftment occurred with minimal immunosuppression.
This observation suggests the emergence of immune tolerance in
the graft-versus-host direction across HLA barriers beyond a full
haplotype. It also demonstrates the existence of hematopoietic
progenitors in a liver graft capable of reconstituting in an adult
patient.PHARMACY
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EFFECT OF NEBULIZED DORNASE ALFA ON PULMONARY GAS EXCHANGE
IN CRITICALLY ILL STEM CELL TRANSPLANT RECIPIENTS
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Center, Houston, TX; 2UT M.D. Anderson Cancer Center, Houston, TX
Introduction:Dornase alfa (DA), a recombinant human deoxyribo-
nuclease, is used in non-cystic fibrosis patients primarily for its mu-
colytic properties. The objective of this study was to examine the
effect of DA on gas exchange in critically ill adult cancer patients
with tenacious pulmonary secretions or atelectasis.
Methods: Following IRB approval, medical records of ICU pa-
tients who received nebulized DA for. 72 hrs between 1/1/05
and 10/1/08 were retrospectively studied, including a subset anal-
ysis of stem cell transplant (SCT) patients. The PaO2, FiO2, and
PaO2/FiO2 (PF) ratio at baseline, 24 hrs, and 48 hrs post-DA ad-
ministration were analyzed using the paired t-test and the Wil-
coxon sign rank test. P-values\0.05 were considered
statistically significant, while an improvement in PF ratio by
50% or to a value of 100 above baseline were considered clinically
significant.
Results:During the six-month study period, 109 critically-ill adult
patients underwent treatment with DA, of which 9 (8%) were SCT
recipients. Six patients received allogeneic transplants and 3 re-
ceived autologous transplants. Sixty-seven percent of SCT recipi-
ents had radiographic evidence of pulmonary infiltrates and 33%
had pulmonary collapse. All nine patients were mechanically ven-
tilated. No statistically significant results were observed in SCT
recipients with regards to change in PF ratio or FiO2 from base-
line to 24 or 48 hrs (see Table). The PF ratio increased by 50%
above baseline in 22.2% and 33.3% of SCT recipients at 24 hrs
and 48 hrs, respectively. The PF ratio increased to a value of
100 above baseline in one SCT recipient (11.1%) at 24 hrs and
48 hrs.
Conclusion:Nostatistically or clinically significantpulmonarygas ex-
change benefitswere seen inSCTrecipients whowere treatedwithDA
when used as amucolytic agent. Further research is needed to establish
if DA may be a viable treatment option in critically ill adult SCT
patients.
